Business Context and Reporting Period
This Form 8-K Current Report was filed by Galectin Therapeutics Inc. on May 15, 2017, with the earliest event reported on that date. The filing primarily addresses corporate governance amendments and a new financing arrangement entered into on May 19, 2017.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The only financial figure disclosed relates to a potential future capital raise:
- Proposed Offering Size: Up to $30.0 million in aggregate offering price for common stock.
- Commission Rate: 3.0% of gross proceeds payable to the sales agent.
Material Changes
The filing details two significant material events:
- At Market Issuance Sales Agreement: On May 19, 2017, the Company entered into an agreement with FBR Capital Markets & Co. to sell shares of common stock through an "at the market" offering. FBR will act as the sales agent, and the Company will determine the number of shares, dates, and minimum prices for sales.
- Amendments to Certificate of Incorporation: On May 15, 2017, the Company filed amendments with the State of Nevada to adjust authorized share counts:
- Reduced authorized Series A 12% Convertible Preferred Stock to 1,742,500 shares.
- Reduced authorized Series B-3 Convertible Preferred Stock to 2,508,500 shares.
- Increased authorized Common Stock (Class W) to 12,748,500 shares.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, management commentary on future performance, or a discussion of risks and contingencies beyond the standard terms of the sales agreement. The agreement notes that sales will be made at prevailing market prices and that the Company will pay a 3.0% commission. The text states that the description of the agreement is qualified by reference to the full text filed as Exhibit 10.1.
Investor Verification Checklist
- Verify the current market price of the common stock to assess the potential dilution impact of the $30.0 million offering.
- Review the full text of the At Market Issuance Sales Agreement (Exhibit 10.1) for specific termination rights and sales parameters.
- Confirm the current outstanding share counts of Series A, Series B-3, and Common Stock (Class W) to understand the remaining issuance capacity under the new authorizations.
- Check subsequent filings to determine if and when shares were actually sold under the FBR agreement.